Neil Laird says it is packed with nutrients that protect eyesight and reduce the risk of age-related macular degeneration ...

BrightFocus Foundation launches two national public service announcements encouraging eye exams to save sight from macular ...

OLN324 targets both VEGF and Ang2, the same mechanism of action as Roche’s Vabysmo, the Swiss giant’s multi-blockbuster ...

K8 was found to reduce geographic atrophy lesion area growth by more than 50% in its first human clinical trial of the drug.

Backed by a trio of top venture firms, Ollin is working on a pair of medicines it believes can one-up Roche’s Vabysmo and Amgen’s Tepezza.

Ollin Biosciences has launched with $100 million in series A financing led by Arch Venture Partners, Mubadala Capital, and ...

During his tenure at Roche's Genentech, ophthalmologist Jason Ehrlich, M.D., Ph.D., supported the development of the ...

Our everyday habits, from the food we eat to the way we spend time outdoors, can have a direct and lasting effect on our eye health. What you eat. A balanced diet that includes dark leafy greens, ...

Alteogen Inc. (KOSDAQ:196170) announced today that the European Commission (EC) has granted marketing authorization for EYLUXVI® (code name: ALT-L9), an Eylea® biosimilar co-developed by its ...

Discover which lifestyle moves, drops and other strategies give your eyes relief from screens, allergens, and life in general ...

The company’s platform combines protein engineering with validated pathways to enhance durability, efficacy, and patient outcomes.

LumiThera's key innovation is a device for use by ophthalmologists that improves vision and slows its loss, with a focus on ...